Can a heart drug help beat breast cancer? new trial aims to restore immunotherapy power

NCT ID NCT05741164

Not yet recruiting Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Feb 18, 2026 · Last updated May 13, 2026 · Updated 10 times

Summary

This phase 2 trial tests whether adding the beta-blocker propranolol to the immunotherapy drug pembrolizumab can help shrink tumors in people with advanced triple-negative breast cancer that no longer responds to checkpoint inhibitors. About 37 adults with metastatic or unresectable disease will receive both drugs. The goal is to see if propranolol can re-sensitize the immune system to fight the cancer again.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emory University Hospital

Atlanta, Georgia, 30322, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.

ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA REFRACTORY TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA